

Drug Monograph

Drug Name: **Lanoxin® (digoxin) injection solution**
 Drug Class: **Miscellaneous Antiarrhythmic Agent, Cardiac Glycoside**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Lanoxin is available in a vial of injectable solution in the following strengths: 100 mcg/ml (0.1 mg/ml) and 500 mcg/2ml (0.250 mg/ml).

Manufacturer: DSM Pharmaceuticals, Inc. Greenville, NC 27834

Indications: Lanoxin is indicated for the treatment of mild to moderate heart failure in adults and for the control of ventricular response rate in adult patients with chronic atrial fibrillation. Lanoxin is also indicated for use in increasing myocardial contractility in pediatric patient with heart failure

Costs: \$84.55 per 100 mcg/mL vial, \$109.50 per 500 mcg/2 mL vial Wholesale Acquisition Cost

Summary of Findings: The MO HealthNet Division recommends Open Access status for this product.

Status Recommendation:

<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
<input checked="" type="checkbox"/> Open Access	<input type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Preferred
<input checked="" type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: Jo Klinger, PharmD
 Date: January 20, 2020